Ads
related to: how does acitretin work- Safety & Risk Factor Info
View Metabolic Syndrome Risk Info
For a Psoriasis Treatment Option.
- Important HCP Information
See Psoriasis Treatment Options To
Help Your Patients Find Relief.
- Find Resources For HCPs
Learn About Services To Help
Patients Start And Stay On Therapy.
- Clinical Studies
Review Clinical Trial Results for
a Plaque Psoriasis Treatment.
- Safety & Risk Factor Info
Search results
Results From The WOW.Com Content Network
Acitretin is a metabolite of etretinate, which was used prior to the introduction of acitretin. Etretinate was discontinued because it had a narrow therapeutic index as well as a long elimination half-life (t 1/2 = 120 days), making dosing difficult. In contrast, acitretin's half-life is approximately 2 days.
For secondary prevention of AK, systemic, low-dose acitretin was found to be safe, well tolerated and moderately effective in chemoprophylaxis for skin cancers in kidney transplant patients. [67] Acitretin is a viable treatment option for organ transplant patients according to expert opinion. [48]
Isotretinoin, also known as 13-cis-retinoic acid and sold under the brand name Accutane among others, is a medication used to treat skin diseases like harlequin-type ichthyosis, and lamellar ichthyosis, and severe cystic acne or moderate acne that is unresponsive to antibiotics. [6]
Etretinate has been replaced by acitretin, the free acid (without the ethyl ester). While acitretin is less lipophilic and has a half-life of only 50 hours, it is partly metabolized to etretinate in the body, [ 2 ] so that it is still a long-acting teratogen and pregnancy is prohibited for two years after therapy.
No curative treatment against EV has been found yet. Several treatments have been suggested, and acitretin 0.5–1 mg/day for 6 months is the most effective treatment owing to antiproliferative and differentiation-inducing effects. Interferons can also be used effectively together with retinoids. [citation needed]
Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in people who are refractory to at least one prior systemic therapy (oral) and for the topical treatment of cutaneous lesions in patients with CTCL who have refractory or persistent disease after other therapies or who have not tolerated other therapies (topical).
Ads
related to: how does acitretin work